Data from the largest clinical trial of myelofibrosis patients treated with ruxolitinib (Jakavi, Novartis) support its safety profile and efficacy benefit, as measured in primary and secondary end points, according to a study presented at the 56th Annual Meeting of the American Society of Hematology (ASH) in San Francisco.
MP Diagnostics HTLV Blot 2.4 (MP Biomedicals) has been approved by FDA as the first FDA-licensed supplemental test for human T-cell lymphotropic virus-I/II (HTLV-I/II). It is a qualitative enzyme immunoassay test, which is to be used to confirm the presence of HTLV antibodies as well as to differentiate between HTLV-I and HTLV-II infection.
On the 1-year anniversary of the first G8 summit on dementia, new funding has been announced for a study to research the use of tadalafil (Adcirca, Cialis; Eli Lilly), an erectile dysfunction drug, for the treatment of vascular dementia.
Providers and care teams working to improve the health of overweight and obese patients must keep hypertension detection and management top of mind for this population.
Formulary managers should be alert to the use of opioid painkillers by special populations, such as people with epilepsy, according to findings during a poster session at the American Epilepsy Society annual meeting in Seattle.
Including more nurse practitioners in a greater number of health plans can improve the experiences of patients as well as the bottom line.
Looking to capitalize on California’s decision to expand Medicaid, Blue Shield of California has purchased Care 1st of Monterey Park, which will add 473,000 Medicaid managed-care members to its rolls.
Dr OvbiageleFor recent ischemic stroke patients, using an optimal combination of evidence-based secondary prevention medication classes, compared to not doing so, was associated with 61% lower odds of experiencing a recurrent stroke, according to a study published online in Neurology.
FDA approved a new use for ruxolitinib (Jakafi, Incyte) to treat patients with polycythemia vera (PV), a chronic type of bone marrow disease. Jakafi is the first drug approved by FDA for this condition.
Narrow networks have sparked concern that they will unduly limit patient care and lead to increased patient use of out-of-network providers with higher out-of-pocket costs.
Recently, accountable care organization's aims have broadened to include overseeing patients with cancer, end-stage renal disease and certain other diseases and chronic conditions.
Now that the ACA has eliminated pre-existing conditions, payers have taken on many unknowns when evaluating the massive population of new members coming in from the state and federal exchanges.
Providers, owners and suppliers who owe Medicare money, have been convicted of felonies or have a history of billing abuse will be excluded from enrollment under new rules adopted by the Centers for Medicare and Medicaid Services (CMS).
Drug shortages and manufacturer consolidation are leaving their imprint on the price of some generic drugs.
Researchers generally agree that intense, highly-coordinated care, with an emphasis on changing patient behavior is a key to improving outcomes and reducing costs for complex morbidities.
Nilotinib (Tasigna) should be considered as a leading option for front-line therapy in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), according to data presented at the 56th ASH Annual Meeting and Exposition in San Francisco.
Actavis Plc has announced that the Infective Drugs Advisory Committee, which makes recommendations to the FDA concerning the safety and effectiveness of drug products for use in the treatment of infectious diseases, has voted to recommend approval of its New Drug Application for ceftazidime-avibactam.
Patients taking statins may be at an increased risk for cataracts, according to a study published in the Canadian Journal of Cardiology.
In patients with opioid dependence, buprenorphine and naloxone (Zubsolv, Orexo) sublingual tablet (CIII) demonstrated comparable patient retention in treatment at days 3 and 15 versus generic buprenorphine and Suboxone film respectively, according to data presented at the 25th Annual Meeting and Symposium of the American Academy of Addiction Psychiatry (AAAP) in Aventura, Fla.
Of all the information technology available to hospitals and practices, the patient portal can be especially challenging.
The industry turns to telehealth to lower costs and improve quality.
In at least 37 states, the three largest insures account for 80% of total health plan enrollment, according to a new study by the U.S. Government Accountability Office (GAO).
The industry is challenged by a number of issues in 2015 including cost control, technology threats, and the emerging consumer market.
FDA has approved blinatumomab (Blincyto, Amgen) immunotherapy for the treatment of relapsed or refractory Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia.
This year, the American Heart Association (AHA) Scientific Sessions were held in Chicago, Illinois, from November 15 to 19. Of all of the late-breaking clinical trials presented at AHA 2014, the IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) study of Merck’s low-density lipoprotein cholesterol (LDL-C)-reducing drugs-the statin, Zocor (simvastatin), and the fixed-dose combination, Vytorin (ezetimibe/simvastatin)-stole the show.
Investigational, oral proteasome inhibitor, ixazomib (MLN9708, Takeda) has FDA has granted breakthrough therapy status for the treatment of relapsed or refractory systemic light-chain (AL) amyloidosis. This is the first proteasome inhibitor and first investigational therapy for AL amyloidosis to receive breakthrough therapy designation.
Just 13 health information exchanges (HIEs) out of an available 100 have been evaluated by examining usage information, making it hard to draw conclusions about their impact.
An estimated 50,000 fewer patients died in hospitals and approximately $12 billion was saved between 2010 and 2013 because of reduced hospital-acquired conditions,according to the U.S. Department of Health and Human Services (HHS).
Total national health spending slowed from 4.1% in 2012 to 3.6% in 2013, the slowest rate of growth since it was first tracked in 1960, according to a report from the Office of the Actuary (OACT) at the Centers for Medicare and Medicaid Services (CMS).
